MedTrace Logo

Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children

NCT00299845 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-10-11

No results posted yet for this study

Summary

Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children. The results will provide the beneficial information for the individualized medicine of PPI in children.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

Lansoprazole

Sponsors & Collaborators

  • Osaka University

    lead OTHER

Principal Investigators

  • Junichi Azuma, MD · Graduate School of Pharmaceutical Sciences, Osaka University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299845 on ClinicalTrials.gov